{"analyses":[{"ciLowerLimit":"2.99","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"12.66","groupDescription":"Stratified by geographic region (Asia \\[excluding Japan\\] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (\\<400 vs. \\>/= 400 ng/mL).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"6.15","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.54","upperLimit":"10.16","value":"5.5"},{"groupId":"OG001","lowerLimit":"21.01","upperLimit":"30.61","value":"25.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"336"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with CR or PR as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR=CR+PR","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG000","title":"Sorafenib - Global"},{"description":"Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG001","title":"Atezolizumab + Bevacizumab - Global"}],"paramType":"NUMBER","populationDescription":"Global ITT population with measurable disease at baseline consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment, and had measurable disease at baseline.","reportingStatus":"POSTED","timeFrame":"Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)","title":"ORR by Investigator-Assessment (ORR-INV) Per RECIST v1.1 in the Global Population","type":"SECONDARY","unitOfMeasure":"percentage of participants"}